Skip to main content
    W

    West Pharmaceutical Services Inc (WST)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $417.95
    +1.53 (+0.37%)

    Market Cap: $29.01B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    West Pharmaceutical Services Inc (WST) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    West Pharmaceutical Services (WST) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, West Pharmaceutical Services reported EPS of $2.66, above the $2.18 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +13.96%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.31
    Range$2.19 - $2.44
    13 analysts
    Revenue Consensus
    $833.44M
    Range$804.58M - $870.45M
    14 analysts
    Reports Apr 21, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.35
    Range$2.31 - $2.40
    6 analysts
    EPS Estimate DriftChange to current
    90d ago$2.29+2.4%
    60d ago$2.29+2.4%
    30d ago$2.30+2.0%
    7d ago$2.28+3.0%
    Current$2.35
    Revenue Consensus
    $859.21M
    Range$834.90M - $895.93M
    6 analysts

    Next Report

    WST has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.2% above the $2.04 reported for the quarter ended Dec 31, 2025.

    WST Earnings Call

    The latest WST earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, WST beat 36 and missed 4. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 43.36% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.66$2.18$2.16 - $2.23+22.02%Beat+35.7%141 up, 0 downOct 29, 2026N/A
    Jun 30, 2026$2.37$2.08$2.05 - $2.10+13.94%Beat+28.8%140 up, 2 downJul 23, 2026$872.30M
    Mar 31, 2026$2.13$1.68$1.65 - $1.69+26.79%Beat+46.9%120 up, 3 downApr 23, 2026$844.90M
    Dec 31, 2025$2.04$1.83$1.79 - $1.88+11.48%Beat+12.1%132 up, 0 downFeb 12, 2026$805.00M
    Sep 30, 2025$1.96$1.71$1.65 - $1.72+14.62%Beat+5.9%121 up, 0 downOct 23, 2025$804.60M
    Jun 30, 2025$1.84$1.54$1.43 - $1.54+19.48%Beat+21.1%12N/AJul 24, 2025$766.50M
    Mar 31, 2025$1.45$1.26N/A+15.08%Beat-7.1%81 up, 0 downApr 24, 2025$698.00M
    Dec 31, 2024$1.82$1.71$1.64 - $1.78+6.43%Beat-0.5%90 up, 0 downFeb 13, 2025$748.80M
    Sep 30, 2024$1.85$1.49$1.46 - $1.57+24.16%Beat-14.4%90 up, 0 downOct 24, 2024$746.90M
    Jun 30, 2024$1.52$1.73$1.54 - $1.94-12.14%Miss-28.0%90 up, 0 downJul 25, 2024$702.10M
    Mar 31, 2024$1.56$1.29$1.20 - $1.34+20.93%Beat-21.2%80 up, 0 downApr 25, 2024$695.40M
    Dec 31, 2023$1.83$1.78$1.73 - $1.86+2.81%Beat+3.4%80 up, 0 downFeb 15, 2024$732.00M
    Sep 30, 2023$2.16$1.86$1.80 - $1.94+16.13%Beat+6.4%80 up, 0 downOct 26, 2023$747.40M
    Jun 30, 2023$2.11$1.93$1.85 - $2.13+9.33%Beat-14.6%80 up, 1 downJul 27, 2023$753.80M
    Mar 31, 2023$1.98$1.67$1.50 - $1.83+18.56%Beat-13.9%82 up, 0 downApr 27, 2023$716.60M
    Dec 31, 2022$1.77$1.38$1.34 - $1.41+28.26%Beat-13.2%81 up, 0 downFeb 16, 2023$708.70M
    Sep 30, 2022$2.03$2.12$2.08 - $2.17-4.25%Miss-1.5%60 up, 1 downOct 27, 2022$686.90M
    Jun 30, 2022$2.47$2.21$2.11 - $2.26+11.76%Beat+0.4%60 up, 0 downJul 28, 2022$771.30M
    Mar 31, 2022$2.30$2.12$2.00 - $2.26+8.49%Beat+12.2%61 up, 0 downApr 28, 2022$720.00M
    Dec 31, 2021$2.04$1.92$1.90 - $1.94+6.25%Beat+52.2%60 up, 0 downFeb 17, 2022$730.80M
    Sep 30, 2021$2.06$1.80$1.72 - $1.85+14.44%Beat+79.1%6N/AOct 28, 2021$706.50M
    Jun 30, 2021$2.46$1.74$1.68 - $1.85+41.38%Beat+96.8%6N/AJul 29, 2021$723.60M
    Mar 31, 2021$2.05$1.43$1.36 - $1.50+43.36%Beat+103.0%6N/AApr 29, 2021$670.70M
    Dec 31, 2020$1.34$1.13$1.11 - $1.18+18.58%Beat+63.4%6N/AFeb 18, 2021$580.20M
    Sep 30, 2020$1.15$0.99$0.95 - $1.02+16.16%Beat+45.6%5N/AOct 22, 2020$548.00M
    Jun 30, 2020$1.25$0.92$0.85 - $0.92+35.87%Beat+40.4%4N/AJul 23, 2020$527.20M
    Mar 31, 2020$1.01$0.82$0.79 - $0.85+23.17%Beat+36.5%5N/AApr 23, 2020$491.50M
    Dec 31, 2019$0.82$0.72$0.70 - $0.74+13.89%Beat+12.3%5N/AFeb 13, 2020$470.60M
    Sep 30, 2019$0.79$0.71$0.69 - $0.72+11.27%Beat+3.9%5N/AOct 24, 2019$456.10M
    Jun 30, 2019$0.89$0.72$0.71 - $0.75+23.61%Beat+27.1%5N/AJul 25, 2019$469.70M
    Mar 31, 2019$0.74$0.66$0.64 - $0.67+12.12%Beat+19.4%6N/AApr 25, 2019$443.50M
    Dec 31, 2018$0.73$0.72$0.71 - $0.73+1.39%Beat+14.1%6N/AFeb 14, 2019$422.50M
    Sep 30, 2018$0.76$0.70$0.66 - $0.73+8.57%Beat+13.4%6N/AOct 25, 2018$431.70M
    Jun 30, 2018$0.70$0.67$0.63 - $0.72+4.48%Beat+6.1%6N/AJul 26, 2018$447.50M
    Mar 31, 2018$0.62$0.64$0.62 - $0.65-3.13%Miss+3.3%7N/AApr 26, 2018$415.70M
    Dec 31, 2017$0.64$0.63$0.61 - $0.68+1.59%Beat+18.5%8N/AFeb 15, 2018$415.60M
    Sep 30, 2017$0.67$0.53$0.51 - $0.54+26.42%Beat+26.4%7N/AOct 26, 2017$398.20M
    Jun 30, 2017$0.66$0.65$0.63 - $0.67+1.54%Beat+11.9%6N/AJul 27, 2017$397.60M
    Mar 31, 2017$0.60$0.56N/A+7.14%Beat+13.2%N/AN/AApr 27, 2017$387.70M
    Dec 31, 2016$0.54$0.56N/A-3.57%Miss+14.9%N/AN/AFeb 16, 2017$382.30M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $7.29, up 8.0% from the year before. It was $2.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$7.29+8.0%
    Dec 31, 2024$6.75-16.5%
    Dec 31, 2023$8.08-5.7%
    Dec 31, 2022$8.57N/A
    Dec 31, 2021$8.61+81.3%
    Dec 31, 2020$4.75+46.6%
    Dec 31, 2019$3.24+15.3%
    Dec 31, 2018$2.81+9.3%
    Dec 31, 2017$2.57+17.4%
    Dec 31, 2016$2.19N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,98216
    2026Q2Jun 30, 20267,66115
    2026Q1Mar 31, 20267,53814
    2025Q4Dec 31, 20255,7218
    2025Q3Sep 30, 20256,64416
    2025Q2Jun 30, 20256,43817
    2025Q1Mar 31, 20258,74216
    2024Q4Dec 31, 20248,51113

    2026Q3 Earnings Call

    Opening remarks

    Michele Polinsky Vice President of Communications Good morning, and welcome to West's third quarter earnings conference call, which has been webcast live. With me today on the call are West President and CEO, Michel Lagarde, and West Senior Vice President and CFO, Bob McMahon. Earlier today, we issued our third quarter financial results. A copy of the press release, along with today's slide presentation containing supplemental information for your reference, has been posted in the investors section of the company's website at investor.westpharma.com. Later today, a replay of the webcast will also be available in the investors section of our website. Before we begin, we'd like to remind you that statements made by management during this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. federal securities law. Please refer to the accompanying Safe Harbor statement in today's presentation and press release, in addition to other disclosures made by the company, such as our 10-K and 10-Q, regarding the risks to which the company is subject. During the call, management will also report on certain non-GAAP financial measures, including organic net sales, adjusted operating profit, adjusted operating profit margin, free cash flow, and adjusted diluted earnings per share. The accompanying disclosure statement, as well as reconciliations of these non-GAAP financial measures to the most comparable financial results prepared in conformity with U.S. GAAP, are provided in this morning's press release and today's presentation materials. I'll now turn the call over to our CEO, Michel Lagarde. Michel?

    Michel Lagarde CEO Thank you, Michele, and good morning, everyone. Thanks for joining us today. We're very pleased to welcome you to our earnings call. Before getting into the details of our strong third quarter performance, I want to begin by saying what a privilege it is for me to now be part of Team West. Having joined West two months ago, my priority has been spending time with our global teams, visiting our sites around the world, and meeting with our customers and investors. It's been incredibly rewarding to connect and learn from the company's stakeholder network and start to identify how we can build on our strengths and continue to evolve. These have been valuable conversations, and I'd like to give a few examples. First was my visit to our Eschweiler manufacturing site in Germany. What was immediately apparent was a strong mission-driven culture and teamwork among the colleagues. Confronted with the need to increase output, the team focused on execution and unlocking new efficiencies, for instance, by integrating more automation onto the production floor. This effort is helping to expand capacity and support our global network optimization to improve the service levels for our customers.

    Frequently Asked Questions About WST

    When is West Pharmaceutical Services's next earnings date?

    West Pharmaceutical Services's next earnings report is expected for Feb 10, 2027.

    Did WST beat earnings estimates last quarter?

    Yes. West Pharmaceutical Services reported EPS of $2.66 for the quarter ended Sep 30, 2026, above the $2.18 estimate, a 22.02% surprise.

    What EPS do analysts expect from WST next quarter?

    The consensus EPS estimate for West Pharmaceutical Services for the quarter ending Dec 31, 2026 is $2.31 from 13 analysts, with estimates from $2.19 to $2.44.

    How often does WST beat earnings estimates?

    West Pharmaceutical Services beat the EPS estimate in each of the last 9 quarters, with an average surprise of +17.11%.